Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study.

ABSTRACT:

Background

Rearrangement in anaplastic lymphoma kinase (ALK) occurs in 4-7% of non-small cell lung cancer (NSCLC) cases. Despite improved survival with tyrosine kinase inhibitors (TKIs), treatment resistance remains challenging. This retrospective study analyzed advanced ALK-positive NSCLC patients, focusing on clinical aspects, treatments, resistance, and outcomes.

Methods

Patients diagnosed between January 2009 and December 2021 who received at least one ALK-TKI line at the Karolinska University Hospital, were included. We evaluated crizotinib or 2^nd generation ALK-TKI effectiveness in first-line treatment and lorlatinib in subsequent lines. Overall survival (OS) was defined as from the date of advanced lung cancer diagnosis until the date of last follow-

SUBMITTER: Kamali C 

PROVIDER: S-EPMC11632442 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature